scholarly journals Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kari Hemminki ◽  
Asta Försti ◽  
Markus Hansson
Keyword(s):  
Multiple Myeloma ◽  
Survival Data ◽  
First Year ◽  
Old Patients ◽  
Cancer Data ◽  
Survival Gain ◽  
Long Period ◽  
The Past ◽  
Future Challenges ◽  
The Difference

AbstractSurvival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.

Survival gains in multiple myeloma from 2003 to 2014.

2018 ◽  
Vol 36 (30_suppl) ◽  
pp. 98-98
Author(s):  
Rafael Fonseca ◽  
Anupam B. Jena ◽  
Desi Peneva ◽  
Zoe Clancy
Keyword(s):  
Multiple Myeloma ◽  
Survival Data ◽  
Treatment Options ◽  
The United States ◽  
Novel Therapies ◽  
Full Sample ◽  
The Past ◽  
Improvement In Survival ◽  
Second Wave ◽  
Novel Agent

98 Background: Survival probabilities for patients with multiple myeloma have increased considerably over the past several decades, and a conservative estimate of 5-year survival today is approximately 50%, perhaps higher with optimal treatment. Treatment options for multiple myeloma have grown significantly beginning in 2003 with the approval of bortezomib, followed by approvals for lenalidomide and thalidomide in 2006. The second wave of novel agent approvals began in 2012 with carfilzomib, followed by pomalidomide in 2013. The aim of this study was to estimate the survival gains associated with multiple myeloma therapies after the introduction of novel therapies beginning in 2003 in the United States. Methods: We estimated survival gains for multiple myeloma patients diagnosed in the 5-year period from 2010-2014—who had access to newer therapies like lenalidomide, bortezomib, pomalidomide, and carfilzomib—compared with patients diagnosed in the 5 years prior to the approval of bortezomib (1998–2002). We used data from the Surveillance, Epidemiology, and End Results (SEER) Program cancer registry and a generalized gamma regression survival model. The sample from SEER included patients aged > 18 years who had a diagnosis of multiple myeloma between 1983 and 2014. Results: Of 88,462 patients identified in the full sample, 14,446 patients were diagnosed in 1998–2002 and 25,948 patients were diagnosed in 2010–2014. Overall survival was 51% longer ( P< 0.001) in multiple myeloma patients diagnosed in 2010–2014 than in patients diagnosed in 1998–2002. Patients diagnosed in 2010–2014 had median and mean survival of 1.32 and 2.27 years longer, respectively, than patients diagnosed in 1998–2002. Conclusions: Patients diagnosed with multiple myeloma during 2010–2014 had significant improvement in survival relative to patients diagnosed in 1998–2002. This study found continued improvement in survival in multiple myeloma patients in the most recent 5-years of survival data available, demonstrating the considerable progress made since the wave of multiple myeloma innovation began in 2003.

scholarly journals Clinical profile of multiple myeloma in Asia: An Asian Myeloma Network (AMN) study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8097-8097 ◽  
Author(s):  
Jae Hoon Lee ◽  
Kihyun Kim ◽  
Jin Seok Kim ◽  
Chang Ki Min ◽  
Kazuyuki Shimizu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Survival Data ◽  
Clinical Characteristics ◽  
Overall Response Rate ◽  
Response Rate ◽  
New Drugs ◽  
Asian Countries ◽  
Asian Patients ◽  
The Difference ◽  
Few Data

8097 Background: The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However the difference of clinical characteristics between ethnic groups is not well-defined. In Asian countries the incidence of MM has been lower compared with Western countries. However, there are growing evidences that MM is increasing very rapidly in this region. Until now, only few data of Asian patients has been reported. Asian myeloma network (AMN) decided to analyze the first multinational project to explore clinical characteristics of Asian MM patients and clinical practice performed in Asian countries. Methods: Data were collected from 21 centers from 7 countries and regions were collected retrospectively. Clinical characteristics of 2969 symptomatic MM patients at diagnosis were described. Overall survival (OS) and prognostic factors were analyzed for 2273 patients who have survival data. Results: Median OS was 54 months (95% CI 48.0-60.0). Patients who were diagnosed before 2000 were shorter survival. Transplantation was performed to 513 patients with better survival (84 vs. 45 months, p<0.001). First line treatment of 2339 evaluable patients was analyzed. Overall response rate was 71% with 30%, VGPR or better. New drugs including bortezomib, thalidomide or lenalidomide were combined for 32.5% of all 2339 patients without difference in response rate or OS according to combination. Conclusions: We successfully described clinical characteristics of Asian MM patients and this project will be the base for future studies or clinical trials for Asian MM patients. Updated analyses and comparison with Western data will be presented. AMN, supported by the International Myeloma Foundation (IMF) IMWG initiative.

scholarly journals Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5035-5035
Author(s):  
Jae Hoon Lee ◽  
Kihyun Kim ◽  
Jin Seok Kim ◽  
Chang Ki Min ◽  
Sung-Soo Yoon ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Survival Data ◽  
Clinical Characteristics ◽  
Response Rate ◽  
Conflicts Of Interest ◽  
Asian Countries ◽  
Genetic Characteristics ◽  
Asian Patients ◽  
The Difference ◽  
Few Data

Abstract Abstract 5035 Background: The incidence of multiple myeloma (MM) is known to be variable according to ethnicity. However the difference of clinical characteristics between ethnic groups is not well-defined. In Asian countries the incidence of MM has been lower compared with Western countries. However, there are growing evidences that MM is increasing very rapidly in this region. Until now, only few data of Asian patients has been reported. Asian myeloma network (AMN) decided to analyze the first multinational project to explore clinical characteristics of Asian MM patients and clinical practice performed in Asian countries. Methods: Data were collected from 22 centers from 7 countries and regions were collected retrospectively. Clinical characteristics of 3377 symptomatic MM patients at diagnosis were described. Overall survival (OS) and prognostic factors were analyzed for 3324 patients who have survival data. Results: Clinical and genetic characteristics were summarized at table 1. Median OS was 47 months (95% CI 48. 0–60. 0). Patients who were diagnosed before 2000 were shorter survival. Transplantation was performed to 607 patients with better survival (84 vs 40 months, p<0. 001). First line treatment of 2906 evaluable patients was analyzed. Overall response rate was 71% including VGPR or better 31%. Novel drug-based regimens including bortezomib, thalidomide or lenalidomide were used for 32. 5% of all 2906 patients without difference in response rate or OS. Conclusions: We successfully described clinical characteristics of Asian MM patients and this project will be the base for future studies or clinical trials for Asian MM patients. Updated analyses and comparison with Western data will be presented. AMN, supported by the International Myeloma Foundation (IMF) IMWG initiative. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Bahasa Jepang Sebagai Bahasa Asing -Pemahaman Pembelajar Terhadap Kala-

2019 ◽  
Vol 2 (2) ◽  
pp. 148
Author(s):  
Gede Satya Hermawan
Keyword(s):  
Language Learners ◽  
Experimental Research ◽  
Language Education ◽  
Japanese Language ◽  
First Year ◽  
The Past ◽  
Verb Conjugation ◽  
The Difference

In Indonesian to express time in the past, present, and future only indicated by time adverbs, and no conjugation in the verb. The first-year Japanese language education learners in the Ganesha  University of Education, when they began to understand tenses in Japanese, it was seen that the concept of tenses in Indonesian was interference. The not only verb conjugation in Japanese is an obstacle, but the understanding of concepts Japanese tenses has also become a problem for learners. This paper will explain to the understanding of first-year Japanese language learners when applied Japanese tenses. This research is experimental research, where learners will be given two sentences, and asked to explain the differences. If the learner understands the concept of the Japanese tenses, the learner will find the difference from the time of the event in the sentence. There were 22 learners first-year Japanese language learners who were the subjects of the research. The results obtained are the first-year Japanese language learners of the Ganesha University of Education,  most of whom have not shown a good understanding of the use of Japanese tenses, this is indicated by the number of learners who are right in explaining that there are four people from 22 learners.

Smart Estimation Ver-H.1.0

2018 ◽  
Author(s):  
Sigit Haryadi
Keyword(s):  
Sample Size ◽  
Confidence Level ◽  
Time Span ◽  
Regression Equation ◽  
Weight Factor ◽  
The Past ◽  
Level Of Confidence ◽  
The Future ◽  
Future Value ◽  
The Difference

We cannot be sure exactly what will happen, we can only estimate by using a particular method, where each method must have the formula to create a regression equation and a formula to calculate the confidence level of the estimated value. This paper conveys a method of estimating the future values, in which the formula for creating a regression equation is based on the assumption that the future value will depend on the difference of the past values divided by a weight factor which corresponding to the time span to the present, and the formula for calculating the level of confidence is to use "the Haryadi Index". The advantage of this method is to remain accurate regardless of the sample size and may ignore the past value that is considered irrelevant.

scholarly journals Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma

2021 ◽  
Vol 12 ◽  
pp. 204062072110129
Author(s):  
Songyi Park ◽  
Dong-Yeop Shin ◽  
Junshik Hong ◽  
Inho Kim ◽  
Youngil Koh ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Induction Chemotherapy ◽  
Statistical Significance ◽  
Conditioning Regimen ◽  
Progression Free Survival ◽  
High Dose ◽  
Newly Diagnosed ◽  
Cell Engraftment ◽  
The Difference ◽  
High Dose Melphalan

Background: High dose melphalan (HDMEL) is considered the standard conditioning regimen for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients. Recent studies showed superiority of busulfan plus melphalan (BUMEL) compared to HDMEL as a conditioning regimen. We compared the efficacy of HDMEL and BUMEL in newly diagnosed Asian MM patients, who are often underrepresented. Methods: This is a single-center, retrospective study including MM patients who underwent ASCT after bortezomib-thalidomide-dexamethasone (VTD) triplet induction chemotherapy between January 2015 and August 2019. Result: In the end, 79 patients in the HDMEL group were compared to 31 patients in the BUMEL group. There were no differences between the two groups with regards to sex, age at ASCT, risk group, and stage. The HDMEL group showed better response to pre-transplant VTD compared to BUMEL, but after ASCT the BUMEL group showed better overall response. In terms of progression-free survival (PFS), although BUMEL showed trends towards better PFS regardless of pre-transplant status and age, the difference did not reach statistical significance. The BUMEL group more often experienced mucositis related to chemotherapy, but there was no difference between the two groups with regards to hospitalization days, cell engraftment, and infection rates. Conclusion: BUMEL conditioning deserves attention as the alternative option to HDMEL for newly diagnosed MM patients, even in the era of triplet induction chemotherapy. Specifically, patients achieving very good partial response (VGPR) or better response with triplet induction chemotherapy might benefit the most from BUMEL conditioning. Tailored conditioning regimen, based on patient’s response to induction chemotherapy and co-morbidities, can lead to better treatment outcomes.

scholarly journals The Evolving Field of Genetic Epidemiology: From Familial Aggregation to Genomic Sequencing

2019 ◽  
Vol 188 (12) ◽  
pp. 2069-2077
Author(s):  
Priya Duggal ◽  
Christine Ladd-Acosta ◽  
Debashree Ray ◽  
Terri H Beaty
Keyword(s):  
Genetic Epidemiology ◽  
Disease Risk ◽  
Familial Aggregation ◽  
Rna Expression ◽  
Entire Genome ◽  
The Past ◽  
Future Challenges ◽  
The Individual ◽  
Study Designs ◽  
Health Applications

Abstract The field of genetic epidemiology is relatively young and brings together genetics, epidemiology, and biostatistics to identify and implement the best study designs and statistical analyses for identifying genes controlling risk for complex and heterogeneous diseases (i.e., those where genes and environmental risk factors both contribute to etiology). The field has moved quickly over the past 40 years partly because the technology of genotyping and sequencing has forced it to adapt while adhering to the fundamental principles of genetics. In the last two decades, the available tools for genetic epidemiology have expanded from a genetic focus (considering 1 gene at a time) to a genomic focus (considering the entire genome), and now they must further expand to integrate information from other “-omics” (e.g., epigenomics, transcriptomics as measured by RNA expression) at both the individual and the population levels. Additionally, we can now also evaluate gene and environment interactions across populations to better understand exposure and the heterogeneity in disease risk. The future challenges facing genetic epidemiology are considerable both in scale and techniques, but the importance of the field will not diminish because by design it ties scientific goals with public health applications.

scholarly journals The Burden of the Nondiversifiable Risk of Entrepreneurship

2010 ◽  
Vol 100 (3) ◽  
pp. 1163-1194 ◽  
Author(s):  
Robert E Hall ◽  
Susan E Woodward
Keyword(s):  
Relative Risk ◽  
Risk Aversion ◽  
Venture Capital ◽  
Dynamic Program ◽  
Certainty Equivalent ◽  
Important Class ◽  
Relative Risk Aversion ◽  
The Past ◽  
Equity Value ◽  
The Difference

Entrepreneurship is risky. We study the risk facing a well-documented and important class of entrepreneurs, those backed by venture capital. Using a dynamic program, we calculate the certainty-equivalent of the difference between the cash rewards that entrepreneurs actually received over the past 20 years and the cash that entrepreneurs would have received from a risk-free salaried job. The payoff to a venture-backed entrepreneur comprises a below-market salary and a share of the equity value of the company when it goes public or is acquired. We find that the typical venture-backed entrepreneur received an average of $5.8 million in exit cash. Almost three-quarters of entrepreneurs receive nothing at exit and a few receive over a billion dollars. Because of the extreme dispersion of payoffs, an entrepreneur with a coefficient of relative risk aversion of two places a certainty equivalent value only slightly greater than zero on the distribution of outcomes she faces at the time of her company's launch. (JEL G24, G32, L26, M13)

Hyperthermia and voluntary exhaustion: integrating models and future challenges

2007 ◽  
Vol 32 (4) ◽  
pp. 808-817 ◽  
Author(s):  
Stephen S. Cheung
Keyword(s):  
Heat Storage ◽  
Brain Temperature ◽  
Voluntary Exercise ◽  
Future Research ◽  
Laboratory Studies ◽  
Exertional Heat Illness ◽  
Non Invasive ◽  
The Past ◽  
Future Challenges ◽  
Effects Of Temperature

Over the past decade, research interest has risen on the direct effects of temperature on exercise capacity and tolerance, particular in the heat. Two major paradigms have been proposed for how hyperthermia may contribute to voluntary fatigue during exercise in the heat. One suggests that voluntary exhaustion occurs upon the approach or attainment of a critical internal temperature through impairment in a variety of physiological systems. An alternate perspective proposes that thermal inputs modulate the regulation of self-paced workload to minimize heat storage. This review seeks to summarize recent research leading to the development of these two models for hyperthermia and fatigue and explore possible bridges between them. Key areas for future research and development into voluntary exhaustion in the heat include (i) the development of valid and non-invasive means to measure brain temperature, (ii) understanding variability in perception and physiological responses to heat stress across individuals, (iii) extrapolating laboratory studies to field settings, (iv) understanding the failure in behavioural and physiological thermoregulation that leads to exertional heat illness, and (v) the integration of physiological and psychological parameters limiting voluntary exercise in the heat.

Sign in / Sign up

Export Citation Format

Share Document